3 February 2023

Zensar Technologies Limited (ZENSARTECH)

CMP: ₹235

ANANDRATHI

## Q3-FY23 Result Update

Target: ₹290

- Zensar Technologies Limited (ZENSARTECH) has reported consolidated revenue of ₹11,976 million in Q3-FY22 as against ₹11,025 million in Q3-FY22. In US dollar terms the revenue growth was negative 0.8% YoY and negative 5.9% QoQ at \$145.9 million. The softness was due to the deceleration in the demand environment leading to client's deferring discretionary spend and scaling back budgets.
- On profitability front, the company's consolidated EBITDA margin stood at 11.3% at ₹1,349 million in Q3-FY23 as against 14.4% at ₹1,585 million in same quarter previous year. The consolidated profit after tax (PAT) margin for the company stood 8.9% at ₹1,061 million as against 8.3% at ₹914 million in same quarter previous year. The operating margins during the quarter were lower due to higher operating expenses.
- On segment basis, Banking reported sequential Q-o-Q growth of 7.4% on constant currency basis while Hi-tech, Manufacturing, Insurance, Consumer and Emerging posted de-growth of 4.9%/7%/10.3%/2.3% and23.9% respectively on QoQ basis. The decline was mainly attributable to factors like delay in decision making, forward shifting of milestones, furloughs and macro demand uncertainties. The order book for the quarter ended Q3-FY23 stood at \$130.5 million, supported by healthy renewals and multiple wins across verticals.
- During the quarter, ZENSARTECH has also won significant four deals in Application development services, along with data engineering and data services mandate in US, South Africa, UK etc. During the quarter, the company scaled two clients to the \$10 million-plus bracket.
- In terms of guidance, the management has not given specific guidance however it is confident of scaling back revenues to normal levels going ahead and a healthy pipeline of orders along with gradually improving margins to augur well in medium term.
- We have incorporated latest quarterly numbers for ZENSARTECH and have revised our estimates for the company in terms of both revenues and earnings. We continue to remain positive on the company for medium to long term, we maintain our rating to BUY with a revised target price ₹290 per share.

## ANANDRATHI

## Q3-FY23 results (Consolidated)

(In ₹ mn)	Q3-FY23	Q3-FY22	Chg	9M-FY23	9M-FY22	Chg
Net Sales	11,976	11,025	8.6%	36,356	30,899	17.7%
Operating Expense	10,627	9,440	12.6%	32,592	25,976	25.5%
EBITDA	1,349	1,585	-14.9%	3,764	4,923	-23.5%
Other Income	259	241		756	654	
Depreciation	497	474		1,479	1,368	
EBIT	1,111	1,352	-17.8%	3,041	4,209	-27.8%
Interest	76	89		215	265	
PBT	1,035	1,263	-18.1%	2,826	3,944	-28.3%
Тах	270	339		742	1,036	
Exceptional Items	-	-		-	-	
PAT	765	924	-17.2%	2,084	2,908	-28.3%
Minority /Other Adj.	296	(10)		433	4	
Consolidated PAT	1,061	914	16.1%	2,517	2,912	-13.6%

Margins	Q3-FY23	Q3-FY22	ChgBPS	9M-FY23	9M-FY22	ChgBPS
Operating Margin %	11.3%	14.4%	-311	10.4%	15.9%	-558
Net Margin %	8.9%	8.3%	57	5.7%	9.4%	-368

## Zensar Technologies Limited (ZENSARTECH)

## ANANDRATHI

## **Financials (Consolidated):**

(In ₹ Mn.)	FY-21	FY-22	FY-23E	FY-24E	(In ₹ Mn.)	FY-21	FY-22	FY-23E	FY-24E
Net Sales	37,814	12 120	49,959	E/ 021	<u>Liabilities</u>				
INEL SAIES	57,014	42,438	49,959	54,931	Equity Share Capital	600	677	677	677
Operating Expense	31,892	36,165	44,759	47,676	Reserves & Surplus	22,824	26,191	29,243	33,751
EBITDA	5,922	6,273	5,200	7,255	Total Shareholder's Funds	23,424	26,868	29,920	34,428
Other Income	1 1 0 0	1 660	1 2 4 0	1 272	Minority Interest	288	-	-	-
Other Income	1,180	1,669	1,249	1,373	Long-Term Liabilities	-	-	-	-
Depreciation	1,747	1,848	1,998	2,197	Other Long-term Liabilities	3,239	3,544	3,544	3,544
EBIT	5,355	6,094	4,450	6,431	Deferred Tax Liability	(492)	(539)	(539)	(539)
LDIT					Short-term Liabilities	7,384	8,299	9,770	10,742
Interest	535	353	295	295	Total	33,843	38,172	42,695	48,175
Misc. items	(491)	-	-	-	<u>Assets</u>				
PBT	4 2 2 0	E 7/1	4 165	6 126	Net Fixed Assets	11,330	12,858	12,469	12,261
PDI	4,329	5,741	4,155	6,136	Long-Term L&A	783	950	950	950
Тах	1,259	1,524	1,103	1,629	Non Current Investments	1,540	1,605	1,605	1,605
Minority Interest	(70)	(54)	-	_	Other Non-Current Assets	261	132	132	132
-					Current Asset	19,929	22,627	27,539	33,227
РАТ	3,000	4,163	3,052	4,507	Total	33,843	38,172	42,695	48,175
Margins	FY-21	FY-22	FY-23E	FY-24E	(In ₹ mn)	FY-21	FY-22	FY-23E	FY-24E
Sales Growth %	-9.6%	12.2%	17.7%	10.0%	EPS (₹)	13.3	18.4	13.5	19.9
					P/E (x)	17.8	12.8	17.5	11.8
Operating Margin %	15.7%	14.8%	10.4%	13.2%	P/B (x)	2.3	2.0	1.8	1.5
Net Margin %	7.9%	9.8%	6.1%	8.2%	ROE	12.8%	15.5%	10.2%	13.1%


Source: Company, Anand Rathi Research

Key Risks:

The company's business is exposed to foreign exchange risks.

# AnandRathi

### **Rating and Target Price history:**



**ZENSARTECH** rating history & price chart

Source: Bloomberg, Anand Rathi Research

NOTE: Prices are as on 3 February 2023 close.

## ANANDRATHI

#### **ZENSARTECH** rating details

Date	Rating	Target Price (₹)	Share Price (₹)
21-Jun-21	BUY	360	294
27-July-21	BUY	463	403
08-Nov-21	BUY	562	455
01-Feb-22	BUY	535	424
23-May-22	BUY	427	290
03-Feb-23	BUY	290	235

Source: Bloomberg, Anand Rathi Research

## ANANDRATHI

#### **Analyst Certification**

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

#### **Ratings Methodology**

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>₹300 Billion ) and Mid/Small Caps (<₹300 Billion ) or SEBI definition vide its circularSEBI/HO/IMD/DF3/CIR/P/2017/114 dated 6th October 2017, whichever is higher and as described in the Ratings Table below:</p>

Ratings Guide (12 months)	Buy	Hold	Sell	
Large Caps (>₹300Bn.)	15%	5%-10%	Below 5%	
Mid/Small Caps (<₹300 Bn.)	20%	10%-15%	Below 10%	

## ANANDRATHI

#### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX) and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues.

**General Disclaimer:** - This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up,

Continued...

## ANANDRATHI

Contd.

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i. e. www.rathionline.com

**Disclaimers in respect of jurisdiction:** This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

**Copyright:** - This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Contd.

Contd.

#### Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Sr. No.	Statement	Answers to the Best of the knowledge and belief of the ARSSBL/ its Associates/ Research Analyst who is preparing this report
1	ARSSBL/its Associates/ Research Analyst/ his Relative have any financial interest in the subject company? Nature of Interest (if applicable), is given against the company's name?.	NO
2	ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?.	NO
3	ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report or at the time of public appearance?.	NO
4	ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months.	NO
5	ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months.	NO
6	ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.	NO
7	ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.	NO
8	ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report.	NO
9	ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	NO
10	ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	NO